Literature DB >> 21269001

Neonatal abstinence scores in opioid-exposed and nonexposed neonates: a blinded comparison.

Hendrée E Jones1, Cheryl Harrow, Kevin E O'Grady, Michael Crocetti, Lauren M Jansson, Karol Kaltenbach.   

Abstract

Twenty-nine opioid-exposed and 26 nonopioid-exposed neonates received neonatal abstinence syndrome (NAS) assessment by an examiner blinded to group status twice daily over the first two postnatal days. The opioid-exposed group had higher mean NAS scores than the nonopioid-exposed group. A 3-sign index, consisting of hyperactive moro reflex, mild tremors when undisturbed, and increased muscle tone, showed excellent discrimination between groups. The use of a 3-sign screening index in the days immediately after birth may provide a cost-effective mechanism for the identification of opioid-exposed infants, particularly in infants of women for whom identification of status as a substance user may not be immediately evident. Although a potentially useful screening tool, the 3-sign screening tool should not replace the full assessment of the opioid-exposed infant after birth.

Entities:  

Mesh:

Year:  2010        PMID: 21269001     DOI: 10.5055/jom.2010.0038

Source DB:  PubMed          Journal:  J Opioid Manag        ISSN: 1551-7489


  17 in total

1.  Positive Predictive Value of Administrative Data for Neonatal Abstinence Syndrome.

Authors:  Faouzi I Maalouf; William O Cooper; Shannon M Stratton; Judith A Dudley; Jean Ko; Anamika Banerji; Stephen W Patrick
Journal:  Pediatrics       Date:  2018-12-04       Impact factor: 7.124

Review 2.  Beyond the Finnegan scoring system: Novel assessment and diagnostic techniques for the opioid-exposed infant.

Authors:  Davida M Schiff; Matthew R Grossman
Journal:  Semin Fetal Neonatal Med       Date:  2019-01-28       Impact factor: 3.926

3.  Are male neonates more vulnerable to neonatal abstinence syndrome than female neonates?

Authors:  Annemarie Unger; Reinhold Jagsch; Andjela Bäwert; Bernadette Winklbaur; Klaudia Rohrmeister; Peter R Martin; Mara Coyle; Gabriele Fischer
Journal:  Gend Med       Date:  2011-11-15

4.  Analysis of the factors that influence the Finnegan Neonatal Abstinence Scoring System.

Authors:  E Gomez-Pomar; A Christian; L Devlin; K T Ibonia; V A Concina; H Bada; P M Westgate
Journal:  J Perinatol       Date:  2017-04-06       Impact factor: 2.521

5.  Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison.

Authors:  Annemarie Unger; Reinhold Jagsch; Hendree Jones; Amelia Arria; Harald Leitich; Klaudia Rohrmeister; Constantin Aschauer; Berndadette Winklbaur; Andjela Bäwert; Gabriele Fischer
Journal:  Addiction       Date:  2011-05-12       Impact factor: 6.526

Review 6.  Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence-based approach.

Authors:  Martha L Velez; Chloe J Jordan; Lauren M Jansson
Journal:  Neurotoxicol Teratol       Date:  2021-08-19       Impact factor: 3.763

Review 7.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

8.  Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates.

Authors:  Diann E Gaalema; Teresa Linares Scott; Sarah H Heil; Mara G Coyle; Karol Kaltenbach; Gary J Badger; Amelia M Arria; Susan M Stine; Peter R Martin; Hendrée E Jones
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

9.  The grasp reflex and moro reflex in infants: hierarchy of primitive reflex responses.

Authors:  Yasuyuki Futagi; Yasuhisa Toribe; Yasuhiro Suzuki
Journal:  Int J Pediatr       Date:  2012-06-11

Review 10.  Review of the assessment and management of neonatal abstinence syndrome.

Authors:  Sarah Mary Bagley; Elisha M Wachman; Erica Holland; Susan B Brogly
Journal:  Addict Sci Clin Pract       Date:  2014-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.